Synthetic thyrotropin releasing factor as a test of pituitary thyrotropin reserve
| Autor: | Marcos Calderon, Norman Fleischer, John L. Kirkland, George W. Clayton, Maria Lorente, Rebecca T. Kirkland |
|---|---|
| Rok vydání: | 1972 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty Pituitary gland endocrine system diseases Endocrinology Diabetes and Metabolism Clinical Biochemistry Pituitary Function Tests Radioimmunoassay Thyrotropin Pituitary neoplasm Biochemistry Hypopituitarism Lesion Endocrinology TRH stimulation test Adrenocorticotropic Hormone Internal medicine Iodine Isotopes Myxedema medicine Methods Animals Humans Euthyroid Pituitary Neoplasms Thyrotropin-Releasing Hormone business.industry Goats Biochemistry (medical) Pituitary tumors medicine.disease Thyrotropin-releasing factor medicine.anatomical_structure Pituitary Gland Acromegaly Rabbits medicine.symptom business hormones hormone substitutes and hormone antagonists |
| Zdroj: | The Journal of clinical endocrinology and metabolism. 34(4) |
| ISSN: | 0021-972X |
| Popis: | The iv administration of 0.5 mg of synthetic thyroptropin releasing factor (TRF) to control subjects increased plasma TSH from baseline levels of 2.1 ± 0.01 μU/ml to peak values of from 8.5–27 μU/ml. Plasma TSH levels in subjects with primary myxedema were elevated and rose further following TRF. In seven of 16 euthyroid subjects with pituitary tumors, peak values of plasma TSH following TRF ranged from 2.5–6.5 μU/ml indicating limited reserve for TSH secretion. Subjects with hypothyroidism secondary to Sheehan’s syndrome or pituitary tumors did not alter their plasma TSH levels following TRF indicating inadequate pituitary function. Plasma TSH rose normally following TRF in five subjects with TSH deficiency in the absence of a known organic pituitary lesion. This latter group of subjects may have TRF deficiency as a cause of their decreased TSH secretion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|